A strategically minded, operations-focused executive, Angela specializes in transforming organizations and building strategies that drive sustainable growth. With more than 28 years in drug development, clinical research, and biospecimens, she brings a unique combination of scientific, operational, regulatory, and commercial fluency to every engagement.

Angela excels in leading complex, global clinical enterprises and translating vision into disciplined execution across therapeutic areas and stages of development. As a versatile and visionary operator, she aligns operating models, talent, and technology with board-level priorities and investor expectations—driving transformation while balancing growth, profitability, quality, and risk in regulated environments.

Angela’s leadership style blends strategic clarity with hands-on engagement. She focuses on building high-performing, cross-functional teams and creating the conditions for leaders to excel. Known for simplifying complexity and shaping the narrative around risk and opportunity, Angela brings people together across functions and geographies to create alignment and accelerate results.

Angela thrives at the intersection of strategy, execution, and creativity—translating corporate vision into operating plans, governance structures, and measurable outcomes. Her therapeutic and translational experience spans pre-clinical through commercialization across rare diseases, immunology, hematology, oncology, surgical and post-operative care, gastrointestinal and liver disease, cardiovascular and metabolic disease, endocrinology, neurology, ophthalmology, and medical devices. This breadth enables Angela to assess scientific, operational, and commercial implications quickly and guide teams toward sound, data-informed decisions.

Angela is recognized for delivering high-quality, innovative leadership that drives process improvement, portfolio execution, and customer success—consistently positioning organizations for their next stage of growth.